A latest report has been added to the wide database of Transcatheter Mitral Valve Replacement Market by Infinium Global
Research. This report studies the Transcatheter Mitral Valve Replacement Market by product (transapical implantation and
transfemoral implantation), region (Americas, Europe, Asia-Pacific, and Rest of the World) market status and outlook of global
and major regions, from manufacturers, and end industries. The objective of the study is to identify market sizes of different
segments & countries in recent years and to forecast the values for the next six years. Transcatheter Mitral Valve Replacement
Market provides opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive
landscape, latest trends, and product offerings of the major companies in the Transcatheter Mitral Valve Replacement
Market.
Get a Sample Request: https://www.infiniumglobalresearch.com/reports/sample_request/138
The mitral valve, also known as the bicuspid valve or left atrio-ventricular valve, is a dual-flap valve in the heart that lies
between the left atrium and the left ventricle. The mitral valve and the tricuspid valve are known collectively as the atrio-
ventricular valves because they lie between the atria and the ventricles of the heart. The mitral valve manages blood flow
between left atrium and left ventricle; and prevents backward flow of the blood into left atrium. Mitral regurgitation is
leakage of blood backward through the mitral valve each time the left ventricle contracts. This is a most common mitral valve
disorder that causes abnormal blood flow. As a remedy for this problem, surgeons use mitral surgical vale repair procedures
or transcatheter replacement methods.
Market Insights
Some of the key driving factors attributing to the growth of this market include increasing number of patients with mitral
valve disorders. Approximately 7 million people in the U.S. suffer from mitral regurgitation in the U.S., and they represent
almost 2% of the nation's population. Similarly, approximately the same number of people suffers from the condition in
Europe. This group includes 4.1 million people who have moderate to severe mitral regurgitation. The number of new patients
suffering with mitral regurgitation disease added each year is 250,000. Among these 4.1 million patients, only about 20% or
1.67 million are eligible for the treatment. This creates huge opportunity for the global transcatheter mitral valve replacement
market.
Infinium Global Research